June 2025 CORPORATE OVERVIEW Forward-Looking Statements This overview contains forward-looking statements. These statements relate to, among other things, the sufficiency of our cash position to fund advancement of a broad pipeline; the continued advancement of our pipeline, and expected milestones in 2025, 2026, 2027, and beyond, including the expected timing of (i) reporting initial data from our ongoing Phase 1 clinical trials evaluating PRX012, (ii) results of the Phase 2 clinical trial for coramitug, ( ...